Posaconazole indications and usage: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) (Created page with "__NOTOC__ {{Posaconazole}} {{CMG}}; {{AE}} {{AZ}} ==Indications And Usage== ===Prophylaxis of Invasive Aspergillus and Candida Infections=== Noxafil® delayed-release table...") |
(No difference)
|
Revision as of 04:42, 9 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Indications And Usage
Prophylaxis of Invasive Aspergillus and Candida Infections
Noxafil® delayed-release tablets and oral suspension are indicated for:
- prophylaxis of invasive Aspergillus
- Candida infections in patients of
- 13 years of age and older
- High risk of developing these infections
- Severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy.
Treatment of Oropharyngeal Candidiasis Including Oropharyngeal Candidiasis Refractory to Itraconazole and/or Fluconazole
Noxafil oral suspension is indicated for the treatment of oropharyngeal candidiasis, including oropharyngeal candidiasis refractory to itraconazole and/or fluconazole.[1]
References
Adapted from the FDA Package Insert.